Scoop has an Ethical Paywall
Vertex Statement Regarding Trikafta
Vertex is extremely disappointed that Pharmac has decided not to prioritise funding of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for New Zealand’s cystic fibrosis (CF) patients.
We understand that Pharmac must make choices within a fixed budget, about which patient groups will have access to new, innovative medicines. However, we are surprised by this decision, particularly given their recent public acknowledgment of the clinical impact that Trikafta would have on CF patients in New Zealand.
Vertex remains committed to New Zealand’s CF community and will continue to work collaboratively with Pharmac to find a path forward so that those Kiwis who can benefit from Trikafta have the same access as patients in more than 30 other countries around the world.
New Zealand College of Midwives: Celebrating Midwives Across Aotearoa This International Day Of The Midwife
PPTA Te Wehengarua: Building The Secondary Curriculum On Broken Drafts Is A Serious Risk
Whanganui Regional Museum: Whanganui Makers Bring Textile Traditions To Life During Symposium Weekend
Palmerston North Hospital Foundation: Fundraising For Publicly-Owned Surgical Robot Hits $2 Million Milestone In Less Than Three Months
Otago Shore And Land Trust: Hīkoi O Te Taoka - Larger Than Life Hoiho Statues Go To Auction For Charity
Tertiary Education Union: Historic MECA Negotiations In Polytechnic Sector Begin